Recently, Jincheng Pharm (300233) responded to investors' questions on the investor interaction platform. British American Tobacco announced plans to launch a synthetic nicotine e-cigarette, which has attracted the attention of the market and investors. Some investors asked about the impact of this plan on Jincheng Pharm and whether British American Tobacco is one of its clients.
Jincheng Pharm company responded by stating that the current plan has no significant impact on the company, and they have not confirmed if there is any business dealings with British American Tobacco.
At the same time, investors have inquired with Jincheng Pharm regarding the potential use of nicotine as a raw material for anti-aging medication.
In response, Jincheng Pharmaceutical Company stated that currently the company's nicotine is mainly used in the e-cigarette industry, but they will continue to monitor research developments in other fields. This statement has sparked speculation and attention from the market about the company's future direction.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
